Stifel Nicolaus reiterated their buy rating on shares of Rex Bionics PLC (LON:RXB) in a report released on Friday morning. The brokerage currently has a GBX 100 ($1.25) price objective on the stock.

Separately, Beaufort Securities reissued a speculative buy rating on shares of Rex Bionics PLC in a research report on Tuesday, October 25th.

Rex Bionics PLC (LON:RXB) traded up 11.11% during midday trading on Friday, hitting GBX 25.00. The stock had a trading volume of 5,556 shares. Rex Bionics PLC has a 12-month low of GBX 15.88 and a 12-month high of GBX 48.50. The company’s market cap is GBX 4.46 million. The company has a 50-day moving average price of GBX 22.61 and a 200-day moving average price of GBX 30.57.

About Rex Bionics PLC

Rex Bionics Plc develops, manufactures and commercializes robotic equipment for medical applications. The Company’s robotic equipment REX is a hands-free, self-supporting and independently controlled robotic walking device for use in the rehabilitation of people with mobility impairment. It offers two principal products, REX Rehab and Rex P (Personal), which are focused at the rehabilitation clinic and personal homecare markets.

Receive News & Stock Ratings for Rex Bionics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rex Bionics PLC and related stocks with our FREE daily email newsletter.